Muñoz A, Schrager L K, Bacellar H, Speizer I, Vermund S H, Detels R, Saah A J, Kingsley L A, Seminara D, Phair J P
Department of Epidemiology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD.
Am J Epidemiol. 1993 Feb 15;137(4):423-38. doi: 10.1093/oxfordjournals.aje.a116691.
Incidence of clinical outcomes defining acquired immunodeficiency syndrome (AIDS) may be expected to change as a consequence of progressive immunosuppression and use of chemoprophylaxis before the onset of AIDS. Using Poisson regression methods, we examined trends in the incidence of initial and secondary AIDS-defining illnesses from 1985 to 1991 among 2,627 homosexual men participating in the Multicenter AIDS Cohort Study who were seropositive for human immunodeficiency virus type 1. The incidence of Pneumocystis carinii pneumonia rose steeply until 1987 but has declined since then (p < 0.001), while the other AIDS-defining conditions have showed significant (p < or = 0.039) upward trends. Trends for Kaposi's sarcoma, lymphoma, neurologic disease, and cytomegalovirus/herpes simplex virus infections were explained by progressive immunosuppression, but residual downward and upward trends were present for P. carinii pneumonia and other opportunistic infections (bacterial, fungal, and protozoal infections and wasting syndrome). Despite selection bias, those receiving P. carinii pneumonia chemoprophylaxis showed a significantly lower incidence of P. carinii pneumonia (relative risk = 0.32, 95% confidence interval 0.16-0.63), and the time trends of P. carinii pneumonia were explained by progressive immunosuppression and use of prophylaxis. No significant effects on all other diagnoses were seen in those selected to receive antiretroviral therapy. Secondary diagnoses showed a strongly significant (p < 0.001) increase in non-P. carinii pneumonia and non-Kaposi's sarcoma among those with initial diagnoses of Kaposi's sarcoma. Overall, the trend observed in the incidence of other opportunistic infections underscores the need for developing and testing new strategies to curtail or delay the onset of these diseases.
随着免疫抑制的进展以及在获得性免疫缺陷综合征(AIDS)发病前使用化学预防措施,定义AIDS的临床结局的发生率可能会发生变化。我们使用泊松回归方法,研究了1985年至1991年间2627名参与多中心AIDS队列研究且抗人免疫缺陷病毒1型血清呈阳性的同性恋男性中,初次和继发性AIDS定义疾病的发生率趋势。卡氏肺孢子虫肺炎的发生率在1987年之前急剧上升,但此后有所下降(p<0.001),而其他AIDS定义疾病则呈现出显著(p≤0.039)的上升趋势。卡波西肉瘤、淋巴瘤、神经系统疾病以及巨细胞病毒/单纯疱疹病毒感染的趋势可以通过免疫抑制的进展来解释,但卡氏肺孢子虫肺炎和其他机会性感染(细菌、真菌和原生动物感染以及消瘦综合征)仍存在残余的下降和上升趋势。尽管存在选择偏倚,但接受卡氏肺孢子虫肺炎化学预防的患者卡氏肺孢子虫肺炎的发生率显著降低(相对风险=0.32,95%置信区间0.16-0.63),卡氏肺孢子虫肺炎的时间趋势可以通过免疫抑制的进展和预防措施的使用来解释。在被选择接受抗逆转录病毒治疗的患者中,对所有其他诊断没有显著影响。在初次诊断为卡波西肉瘤的患者中,继发性诊断显示非卡氏肺孢子虫肺炎和非卡波西肉瘤有极显著(p<0.001)的增加。总体而言,其他机会性感染发生率的趋势强调了开发和测试新策略以减少或延迟这些疾病发病的必要性。